The Role of Local Hormone Replacement in Overactive Bladder

  • Dudley RobinsonEmail author
  • Linda Cardozo
Overactive Bladder (U Lee and S Adelstein, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Overactive Bladder


Purpose of Review

Overactive bladder (OAB) is a common and distressing condition which is known to increase with age and to have a significant effect on quality of life (QoL). Whilst OAB is a symptomatic diagnosis, many patients will require basic investigations prior to initiating the appropriate management. This paper will explore the prevalence and pathophysiology of OAB as well as diagnosis and management of the condition.

Recent Findings

There is increasing evidence that local oestrogen therapy may be beneficial in the management of postmenopausal women with OAB, either when used alone or as combination therapy with an antimuscarinic drug. This paper will review the postulated mechanisms of action as well as exploring the available evidence base supporting efficacy.


There is now a substantial evidence base to support the use of local vaginal oestrogen therapy in postmenopausal women with OAB either in isolation or alternatively as an adjunctive therapy when used with antimuscarinic medication. Available evidence supports an improvement in lower urinary tract symptoms as well as a significant improvement in health-related quality of life (HRQoL).


Oestrogen Vaginal oestrogen Overactive bladder OAB Detrusor overactivity Antimuscarinics 


Compliance with Ethical Standards

Conflict of Interest

Dudley Robinson has received fees for Consultancy work and Speaking from Astellas, Allergan, Ixaltis, Contura and Ferring. He has performed Research with Astellas, Ixaltis and Allergan. Linda Cardozo has received fees for Consultancy work and Speaking from Atlantic Therapeutics, Boston and Allergan.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynaecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21:5–26. Standardisation of lower urinary tract terminology document. PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Stewart WF, Corey R, Herzog AR, et al. Prevalence of overactive bladder in women: results from the NOBLE program. Int Urogynaecol. J. 2001;12(3):S66.Google Scholar
  3. 3.
    Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87(9):760–6.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Anderson KE. The overactive bladder: pharmacologic basis of drug treatment. Urology. 1997;50:74–89.CrossRefGoogle Scholar
  5. 5.
    Hashim H, Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity? J Urol. 2006;175:191–5.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Caulfield MP, Birdsall NJ. International Union of Pharmacology XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev. 1998;50:279.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Braverman AS, Ruggieri MR. The M2 receptor contributes to contraction of the denervated rat urinary bladder. Am J Physiol. 1998;275:1654.Google Scholar
  8. 8.
    Cartwright R, Panayi D, Cardozo L, Khullar V. Reliability and normal ranges for the Patient’s Perception of Intensity of Urgency Scale in asymptomatic women. BJU Int. 2010;105:832–6.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Cardozo L, Coyne KS, Versi E. Validation of the urgency perception scale. BJU Int. 2005;95:591–6.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Nixon A, Colman S, Sabounjian L, et al. A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. JUrol. 2005;174:604–7.Google Scholar
  11. 11.
    Jenkinson C, Coulter A, Wright L. Short Form 36 (SF-36) health survey questionnaire. Normative data for adults of working age. British Medical Journal. 1993;306:1437–40.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. British Journal of Obstetrics and Gynaecology. 1997;104:1374–9.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Swithinbank L, Hashim H, Abrams P. The effect of fluid intake on urinary symptoms in women. J Urol. 2005 Jul;174(1):187–9.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Subak LL, Wing R, West DS, Franklin F, Vittinghoff E, Creasman JM, et al. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med. 2009;360(5):481–90.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Jeffcoate TNA, Francis WJA. Urgency incontinence in the female. American Journal of Obstetrics and Gynecology. 1966;94:604–18.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Berghmans LC, Hendricks HJ, de Bie RA, van Waalwijk van Doorn ES, Bo K, van Kerrebroeck PE. Conservative treatment of urge urinary incontinence in women: a systematic review of randomised clinical trials. British Journal of Urology International. 2000;85:254–63.CrossRefGoogle Scholar
  17. 17••.
    NICE Guideline (NG123). The Management of Urinary Incontinence in Women. Department of Health. 2019. Recent update of the National UK guidelines.
  18. 18••.
    Dumoulin C, Adewuyi T, Booth J, Bradley C, Burgio K, Hagen S, Hunter K, Imamura M, Morin M, Morkved K, Thakar R, Wallace S, Williams K. Adult Conservative Management. In: Incontinence, 6th Edition. Abrams P, Cardozo L, Wagg A, Wein A, editors. IUCD ICS 1443-1628. 2017. Sixth report of the International Consultation on Incontinence. Google Scholar
  19. 19••.
    Prasad Rai B, Cody JD, Alhasso AA, Stewart L. Anticholinergic drugs versus non drug active therapies for overactive bladder syndrome in adults. Cochrane Database of Systematic Reviews. 2012. review examining the efficacy of antimuscarinic therapy in overactive bladder.
  20. 20••.
    Andersson KE, Cardozo L, Cruz F, Lee KS, Sahai A, Wein AJ. Pharmacological treatment of urinary incontinence. In Incontinence, 6th Edition. Abrams P, Cardozo L, Wagg A, editors. Wein IUCD ICS 805 - 958. 2017. Sixth report of the International Consultation on Incontinence. Google Scholar
  21. 21.
    Hadorn DC, Baker D, Hodges JS, Hicks N. Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol. 1996;49(7):749–54.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ. 2001;323:334–6.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543–62.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Araklitis G, Thiagamoorthy G, Hunter J, Rantell A, Robinson D, Cardozo L. Anticholinergic prescription: are healthcare professionals the real burden? Int Urogynaecol J. 2017;28:1249–56.CrossRefGoogle Scholar
  25. 25.
    Fox C, Smith T, Maidment I, Chan WY, Bua N, Myint PK, et al. Effect of medications with anticholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing. 2014;43:604–15.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Fox C, Richardson K, Maidment ID, Savva GM, Matthews FE, Smithard D, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011;59:1477–83.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27•.
    Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics ad incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175:401–7. A prospective study looking at the association of anticholinergic drug usage and the long term risk of cognitive decline.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28••. An Anticholinergic Burden scale which is useful in clinical practice.
  29. 29.
    Andersson KE, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev. 2004;84:935–86.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Otsuka A, Shinbo H, Matsumoto R, Kurita Y, Ozono S. Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedebergs Arch Pharmacol. 2008;377:473–81.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Sacco E, Bientinesi R, Tienforti D, Racioppi M, Gulino G, D'Agostino D, et al. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence. Expert Opin Drug Discov. 2014;9:433–48.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Hicks A, McCafferty G, Riedel E, Aiyar N, Pullen M, Evans C, et al. GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog. J Pharmacol Exp Ther. 2007;323:202–9.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Khullar V, Amarenco G, Angulo JC, Cambronero J, Hoye K, Milsom I, et al. Efficacy and tolerability of mirabegron, a beta 3 adrenoreceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase III trial. Eur Urol. 2013;63:283–95.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T, et al. Randomised double-blind, active-controlled phase III study to assess 12 month safety and efficacy of mirabegron, a beta 3 adrenoreceptor agonist, in overactive bladder. Eur Urol. 2013;63:296–305.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, et al. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double blind muticentre phase 3B study (BESIDE). Eur Urol. 2016;70:136–45.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Cheng CL, Li JR, Lin CH, de Groat WC. Positive association of female overactive bladder symptoms and oestrogen deprivation: a nationwide population based cohort study in Taiwan. Medicine (Baltimore). 2016;95:e4107.CrossRefGoogle Scholar
  37. 37.
    Hong SK, Yang JH, Kim TB, Kim SW, Paick JS. Effects of ovariectomy and oestrogen replacement on the function and expression of Rho-kinase in rat bladder smooth muscle. BJU Int. 2006;98:1114–7.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Yoshida J, Aikawa K, Yoshimura Y, Shishido K, Yanagida T, Yamaguchi O. The effects of ovariectomy and oestrogen replacement on acetylcholine release from nerve fibres and passive stretch induced acetylcholine release in female rats. Neurourol Urodyn. 2007;26:1050–5.PubMedCrossRefGoogle Scholar
  39. 39.
    Petkov GV. Central role of the BK channel in urinary bladder smooth muscle physiology and pathophysiology. Am J Physiol Requl Integr Comp Physiol. 2014;307:R571–84.CrossRefGoogle Scholar
  40. 40.
    Xin W, Li N, Fernandes VS, Chen B, Rovner ES, Petkov GV. BK Channel regulation by phoshodiesterase type 1: a novel signaling pathway controlling human detrusor smooth muscle function. Am J Physiol Renal Physiol. 2016;310:F994–9.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Provence A, Hristov KL, Parajuli SP, Petkov GV. Regulation of guinea pig detrusor smooth muscle excitability by 17β oestradiol: the role of the large conductance voltage and Ca2+ activated K+ channels. PLoS One. 2015;10:e0141950.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Hristov KL, Parajuli SP, Provence A, Rovner ES, Petkov GV. Nongenomic modulation of the larger conductance voltage and Ca2+ activated K+ channels by oestrogen: a novel regulatory mechanism in human detrusor smooth muscle. Physiol Rep. 2017;5:e13351.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Chen HY, Chen CJ, Chen WC, Wang SJ, Chen YH. A promising protein responsible for overactive bladder in ovariectomised mice. Taiwan J Obstet Gynaecol. 2017;56:196–203.CrossRefGoogle Scholar
  44. 44.
    Samsicoe G, Jansson I, Mellstrom D, Svanberg A. Urinary incontinence in 75 year old women. Effects of oestriol. Acta. Obstet. Gynaecol. Scand. 1985;93:57.Google Scholar
  45. 45.
    Cardozo LD, Rekers H, Tapp A, Barnick C, Shepherd A, Schussler B, et al. Oestriol in the treatment of postmenopausal urgency: a multicentre study. Maturitas. 1993;18:47–53.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Benness C, Wise BG, Cutner A, Cardozo LD. Does low dose vaginal oestradiol improve frequency and urgency in postmenopausal women. Int. Urogynaecol. J. 1992;3(2):281.Google Scholar
  47. 47.
    Eriksen PS, Rasmussen H. Low dose 17β-oestradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study. Eur. J. Obstet. Gynaecol. Reprod. Biol. 1992;44:137–44.CrossRefGoogle Scholar
  48. 48.
    Cardozo L, Lose G, McClish D, Versi E. Estrogen treatment for symptoms of an overactive bladder, results of a meta analysis. Int J Urogynaecol. 2001;12(3):V.Google Scholar
  49. 49•.
    Tseng LH, Wang AC, Chang YL, Soong YK, Lloyd LK, Ko YJ. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome. Neurourol Urodyn. 2009;28(1):47–51. A small but important study examining the synergistic usage of vaginal oestrogen therapy and antimuscarinic medication in the management of OAB. PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50•.
    Nelken RS, Ozel BZ, Leegant AR, Felix JC, Mishell DR. Radomised trial of oestradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. Menopause. 2011;18:962–6. A small but important study examining the synergistic usage of vaginal oestrogen therapy and antimuscarinic medication in the management of OAB. PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Jiang F, Zhu L, Xu T, Gong MY, Huang YL, Li HF, et al. Menopause. 2016;23:451–7. A small but important study examining the synergistic usage of vaginal oestrogen therapy and antimuscarinic medication in the management of OAB. Google Scholar
  52. 52•.
    Chughtai B, Forde JC, Buck J, Asfaw T, Lee R, Te AE, et al. The concomitant use of fesoterodine and topical vaginal oestrogen in the management of overactive bladder and sexual dysfunction in post menopausal women. Post Reprod Health. 2016;22:34–40 A small but important study examining the synergistic usage of vaginal oestrogen therapy and antimuscarinic medication in the management of OAB.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53•.
    Serati M, Salvatore S, Uccella S, Cardozo L, Bolis P. Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity? Eur Urol. 2009;55(3):713–9. A small but important study examining the synergistic usage of vaginal oestrogen therapy and antimuscarinic medication in the management of detrusor overactivity. PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54••.
    Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in postmenopausal women. Cochrane Database Syst Rev. 2012:CD001405. A Cochrane review of the use of topical and systemic oestrogen therapy in postmenopausal women with urinary incontinence. Google Scholar
  55. 55••.
    Weber MA, Kleijn MH, Langendam M, Limpens J, Heineman MJ, Roovers JP. Local Oestrogen for pelvic floor disorders: a systematic review. PLoS One. 2015;10(9):e0136265. A systematic review of local oestrogen therapy in the management of pelvic floor dysfunction. PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of UrogynaecologyKings College HospitalLondonUK

Personalised recommendations